Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AB-201 + cyclophosphamide + fludarabine
- Development stage
- Discontinued
- Lead developer
- Artiva Biotherapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
**AB-201 + cyclophosphamide + fludarabine** is an investigational multi-drug regimen used in clinical trials for patients with advanced HER2-positive solid tumors, such as breast and gastric/gastroesophageal junction cancers. AB-201 is an allogeneic HER2-targeted chimeric antigen receptor NK (CAR-NK) cell therapy developed for outpatient treatment of solid tumors. Cyclophosphamide and fludarabine are chemotherapeutic agents used as lymphodepleting preparatory agents to facilitate adoptive cell therapy by decreasing host immune response and increasing engraftment and efficacy of the infused cell product.
- Other names
- AB-201 + cyclophosphamide + fludarabine
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on AB-201 + cyclophosphamide + fludarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AB-201 + cyclophosphamide + fludarabine.